Immunotherapy in Melanoma | Specialty

A Focus on Pathways: Evolving Role of Oncolytic Immunotherapy in Melanoma

July 21st 2015

Advances in the field of immunotherapy and targeted therapy have brought about new recommendations for patients with melanoma.

FDA Grants Peptide Vaccine Orphan Status for Ovarian Cancer

July 17th 2015

The FDA has granted an orphan drug designation to the immunotherapy DPX-Survivac as a treatment for women with ovarian cancer.

Targeted Therapies, Combination Protocols Are Revolutionizing Treatment for Advanced Melanoma

July 14th 2015

Melissa A. Wilson, MD, PhD, discusses how targeted therapies and combination protocols are revolutionizing the treatment paradigm of advanced melanoma.

Dr. Arkenau on Dabrafenib Combined With Trametinib for BRAF-mutated Melanoma

July 7th 2015

Hendrik-Tobias Arkenau, MD, PhD, executive medical director, Drug Development Unit, Sarah Cannon Research Institute-United Kingdom, discusses the overall survival results of the COMBI-d study, which examined the combination of dabrafenib and trametinib for the treatment of patients with unresectable or metastatic BRAF V600-mutated melanoma.

How a Rebellious Scientist Helped Launch the Modern Age of Immunotherapy

July 5th 2015

James P. Allison, PhD, was honored in the Scientific Advances category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.

FDA Extends Cobimetinib Review Period in Advanced Melanoma

July 1st 2015

The FDA has extended the review period for the MEK inhibitor cobimetinib in combination with the BRAF inhibitor vemurafenib (Zelboraf) for patients with BRAFV600 mutation-positive advanced melanoma by 3 months, making the new decision date November 11, 2015.

Immunotherapy in Melanoma: What Does the Future Hold?

June 25th 2015

Howard L. Kaufman, MD, discusses the rapidly advancing immunotherapy armamentarium in melanoma.

Interpreting PD-L1 Status Among Key Melanoma Topics at ASCO

June 25th 2015

OncLive sat down with Jason J. Luke, MD, discusses the key areas in the treatment of melanoma discussed at the 2015 ASCO Annual Meeting included selecting appropriate immunotherapy regimens based on PD-L1 status and improving surgical practices.

Dr. Ernstoff Discusses Nivolumab and Ipilimumab in Advanced Melanoma

June 23rd 2015

Marc Ernstoff, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses results from a study examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced BRAF-mutated or BRAF wild-type melanoma.

First PD-1 Inhibitor Approved in Europe

June 22nd 2015

The European Commission has approved nivolumab as a treatment for patients with advanced melanoma in the first- and later-line setting regardless of BRAF mutation status, making it the first PD-1 inhibitor to gain approval in Europe.

Frontline BRAF/MEK Combo Improves Survival in Melanoma

June 11th 2015

Combination MEK/BRAF inhibition with trametinib and dabrafenib reduced the risk of death by 29% in patients with BRAF-mutant advanced melanoma.

Wolchok Discusses Frontline Nivolumab/Ipilimumab Combo in Melanoma

June 10th 2015

Jedd D. Wolchok, MD, discusses the unique design and goals of the CheckMate-067 trial, and what its results mean for patients with advanced melanoma going forward.

2015 ASCO Annual Meeting Highlights

June 5th 2015

Frontline Nivolumab Regimens Significantly Improve PFS Versus Ipilimumab in Melanoma

May 31st 2015

Frontline nivolumab as monotherapy and in combination with ipilimumab more than doubled progression-free survival versus ipilimumab alone in patients with advanced melanoma.

Study Disputes Lymph Node Removal Standard in Melanoma

May 31st 2015

Patients with melanoma who are found to have micrometastases after an initial positive sentinel node biopsy can safely forgo a complete lymph node dissection, thus avoiding the risk of debilitating adverse events from the surgery.

Pivotal T-VEC Data Published Ahead of FDA Approval Decision

May 27th 2015

At a recent FDA joint advisory committee meeting, members voted 22-1 to recommend approval of the oncolytic immunotherapy talimogene laherparepvec as a treatment for patients with advanced melanoma.

As FDA Considers Approval, Weber Discusses Adjuvant Ipilimumab in Melanoma

May 26th 2015

To better understand the impact of the EORTC 18071 trial, the chances of approval in the adjuvant setting, and the challenges concerning the dosage and toxicity with ipilimumab, OncLive spoke with the study's lead author Jeffrey S. Weber, MD, PhD.

Managing Checkpoint Agents' Immune-Related Toxicities

May 20th 2015

As immunotherapy agents enter into greater clinical use in oncology, clinicians are learning to manage immune-related adverse events related to the mechanism of action of these new drugs.

Optimization of Melanoma Treatment Advances Remains a Work in Progress

May 19th 2015

Immunotherapies and targeted therapies have led to significant strides in the treatment of patients with melanoma. However, determining which therapies are best for which patients and how to treat patients who don't respond or stop responding to these new therapies is still a challenge. For further insight on optimizing the recent treatment breakthroughs in melanoma, OncLive spoke with Alan Bryce, MD, medical director of the Genomic Oncology Clinic at Mayo Clinic.

Dr. Kevin Kim on T-VEC in Melanoma

May 14th 2015

Kevin B. Kim, MD, medical oncology, California Pacific Medical Center, discusses T-VEC as a treatment option for melanoma.